Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 16/04/21 | Issuer sale | Director | 46,250 | 0.0993% | ||
| 16/04/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 16/04/21 | Free | Chief Financial Officer | 569,947 | 1.2238% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| -0.38% | -0.99% | +42.69% | +100.85% | 67.82B | |
| -0.46% | -2.35% | +33.47% | +78.54% | 63.22B | |
| -0.31% | +3.67% | -12.96% | +374.95% | 27.58B | |
| +0.86% | +2.12% | -7.74% | -13.34% | 26.06B | |
| +1.69% | -0.36% | +26.48% | +15.46% | 25.38B | |
| +1.54% | +1.26% | +25.01% | -17.50% | 19.89B | |
| +1.15% | -5.02% | +219.82% | +379.02% | 17.4B | |
| -0.49% | -0.37% | -7.31% | +524.84% | 14.95B | |
| -0.20% | +8.00% | +55.78% | +167.98% | 14.62B | |
| Average | +0.34% | +1.67% | +41.69% | +178.98% | 30.77B | |
| Weighted average by Cap. | +0.15% | +0.90% | +36.66% | +139.90% |
Employees
51
